BioRestorative Therapies ( (BRTX) ) has shared an announcement.
BioRestorative Therapies, a regenerative medicine company, announced promising developments in their stem cell-based therapies, reporting financial progress and a provisional license for processing non-autologous donor tissue. The company shared advancements in their BRTX-100 clinical trials for lumbar disc disease and their ThermoStem program aimed at metabolic disorders, while also noting increased revenue from BioCosmeceutical products. With no outstanding debt and a strong financial position, BioRestorative is poised for continued growth in the innovative stem cell therapy market.
For an in-depth examination of BRTX stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Paramount Global (NASDAQ:PARA) Gains From Yellowstone in Europe
- Ford (NYSE:F) Shares Slip After Huge New Fine
- Intel (NASDAQ:INTC) Notches Up Despite New Loss to AMD Processors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
